Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the field caused by the FDA Modernization Act 2.0, set an exciting precedent during 2023. However, the translation rates of oncology therapeutics into the clinic remain at 20%, proving there remained a large unmet need for tools to support drug development efforts in a patient-specific context at the preclinical and early translational levels.

At the 8^th Annual Tumor Models San Francisco Summit, attendees gained practical insights into the latest updates across the West Coast and beyond through 25+ case studies that empowered their candidate selection workflows. They joined us to learn from and meet pioneers in preclinical and translational oncology which accelerated candidate’s clinical translatability with optimized efficiency, and cost-effectiveness!